Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors

References

1. 1.↵
   2. Gong J,
   3. Chehrazi-Raffle A,
   4. Reddi S,
   5. Salgia R.

   Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018; 6: 8.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   2. Jiang X,
   3. Wang J,
   4. Deng X,
   5. Xiong F,
   6. Ge J,
   7. Xiang B, et al.

   Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019; 18: 10.

   OpenUrlPubMed
3. 3.↵
   2. Han Y,
   3. Liu D,
   4. Li L.

   PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020; 10: 727–42.

   OpenUrl
4. 4.↵
   2. Tang J,
   3. Shalabi A,
   4. Hubbard-Lucey VM.

   Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2018; 29: 84–91.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Jia L,
   3. Zhang Q,
   4. Zhang R.

   PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biol Med. 2018; 15: 116–23.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   2. Lin H,
   3. Wei S,
   4. Hurt EM,
   5. Green MD,
   6. Zhao L,
   7. Vatan L, et al.

   Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018; 128: 805–15.

   OpenUrlCrossRefPubMed
7. 7.↵
   2. Agata Y,
   3. Kawasaki A,
   4. Nishimura H,
   5. Ishida Y,
   6. Tsubata T,
   7. Yagita H, et al.

   Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996; 8: 765–72.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   2. Zou W,
   3. Chen L.

   Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008; 8: 467–77.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   2. Kansy BA,
   3. Concha-Benavente F,
   4. Srivastava RM,
   5. Jie HB,
   6. Shayan G,
   7. Lei Y, et al.

   PD-1 status in CD8(+) T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res. 2017; 77: 6353–64.

   OpenUrlAbstract/FREE Full Text
10. 10.
    2. Garnelo M,
    3. Tan A,
    4. Her Z,
    5. Yeong J,
    6. Lim CJ,
    7. Chen J, et al.

    Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut. 2017; 66: 342–51.

    OpenUrlAbstract/FREE Full Text
11. 11.
    2. Shen T,
    3. Zhou L,
    4. Shen H,
    5. Shi C,
    6. Jia S,
    7. Ding GP, et al.

    Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. Sci Rep. 2017; 7: 7848.

    OpenUrl
12. 12.↵
    2. Kotsakis A,
    3. Kallergi G,
    4. Aggouraki D,
    5. Lyristi Z,
    6. Koinis F,
    7. Lagoudaki E, et al.

    CD8(+) PD-1(+) T-cells and PD-L1(+) circulating tumor cells in chemotherapy-naive non-small cell lung cancer: towards their clinical relevance? Ther Adv Med Oncol. 2019; 11: 1758835919853193.

    OpenUrl
13. 13.↵
    2. Yeong J,
    3. Lim JCT,
    4. Lee B,
    5. Li H,
    6. Ong CCH,
    7. Thike AA, et al.

    Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. J Immunother Cancer. 2019; 7: 34.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    2. Xiao X,
    3. Lao XM,
    4. Chen MM,
    5. Liu RX,
    6. Wei Y,
    7. Ouyang FZ, et al.

    PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 2016; 6: 546–59.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    2. Wu H,
    3. Xia L,
    4. Jia D,
    5. Zou H,
    6. Jin G,
    7. Qian W, et al.

    PD-L1(+) regulatory B cells act as a T cell suppressor in a PD-L1-dependent manner in melanoma patients with bone metastasis. Mol Immunol. 2020; 119: 83–91.

    OpenUrl
16. 16.↵
    2. Largeot A,
    3. Pagano G,
    4. Gonder S,
    5. Moussay E,
    6. Paggetti J.

    The B-side of cancer immunity: the underrated tune. Cells. 2019; 8: 449.

    OpenUrlPubMed
17. 17.↵
    2. Liu Y,
    3. Cheng Y,
    4. Xu Y,
    5. Wang Z,
    6. Du X,
    7. Li C, et al.

    Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017; 36: 6143–53.

    OpenUrl
18. 18.↵
    2. Concha-Benavente F,
    3. Kansy B,
    4. Moskovitz J,
    5. Moy J,
    6. Chandran U,
    7. Ferris RL.

    PD-L1 mediates dysfunction in activated PD-1(+) NK cells in head and neck cancer patients. Cancer Immunol Res. 2018; 6: 1548–60.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    2. Krempski J,
    3. Karyampudi L,
    4. Behrens MD,
    5. Erskine CL,
    6. Hartmann L,
    7. Dong H, et al.

    Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol. 2011; 186: 6905–13.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    2. Gordon SR,
    3. Maute RL,
    4. Dulken BW,
    5. Hutter G,
    6. George BM,
    7. McCracken MN, et al.

    PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545: 495–9.

    OpenUrlCrossRefPubMed
21. 21.↵
    2. Kuang DM,
    3. Zhao Q,
    4. Peng C,
    5. Xu J,
    6. Zhang JP,
    7. Wu C, et al.

    Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009; 206: 1327–37.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    2. Herbst RS,
    3. Soria JC,
    4. Kowanetz M,
    5. Fine GD,
    6. Hamid O,
    7. Gordon MS, et al.

    Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515: 563–7.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    2. Hartley GP,
    3. Chow L,
    4. Ammons DT,
    5. Wheat WH,
    6. Dow SW.

    Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. Cancer Immunol Res. 2018; 6: 1260–73.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    2. Wang TT,
    3. Zhao YL,
    4. Peng LS,
    5. Chen N,
    6. Chen W,
    7. Lv YP, et al.

    Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut. 2017; 66: 1900–11.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    2. Lv Y,
    3. Zhao Y,
    4. Wang X,
    5. Chen N,
    6. Mao F,
    7. Teng Y, et al.

    Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-alpha-PD-L1 pathway. J Immunother Cancer. 2019; 7: 54.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    2. Nam S,
    3. Lee A,
    4. Lim J,
    5. Lim JS.

    Analysis of the expression and regulation of PD-1 protein on the surface of myeloid-derived suppressor cells (MDSCs). Biomol Ther (Seoul). 2019; 27: 63–70.

    OpenUrl
27. 27.↵
    2. Qian X,
    3. Zhang Q,
    4. Shao N,
    5. Shan Z,
    6. Cheang T,
    7. Zhang Z, et al.

    Respiratory hyperoxia reverses immunosuppression by regulating myeloid-derived suppressor cells and PD-L1 expression in a triple-negative breast cancer mouse model. Am J Cancer Res. 2019; 9: 529–45.

    OpenUrl
28. 28.↵
    2. Kurachi M.

    CD8(+) T cell exhaustion. Semin Immunopathol. 2019; 41: 327–37.

    OpenUrl
29. 29.↵
    2. Chen L,
    3. Han X.

    Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015; 125: 3384–91.

    OpenUrlCrossRefPubMed
30. 30.↵
    2. Latchman YE,
    3. Liang SC,
    4. Wu Y,
    5. Chernova T,
    6. Sobel RA,
    7. Klemm M, et al.

    PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A. 2004; 101: 10691–6.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    2. Francisco LM,
    3. Salinas VH,
    4. Brown KE,
    5. Vanguri VK,
    6. Freeman GJ,
    7. Kuchroo VK, et al.

    PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009; 206: 3015–29.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    2. Diskin B,
    3. Adam S,
    4. Cassini MF,
    5. Sanchez G,
    6. Liria M,
    7. Aykut B, et al.

    PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat Immunol. 2020; 21: 442–54.

    OpenUrlPubMed
33. 33.↵
    2. Wang X,
    3. Wang G,
    4. Wang Z,
    5. Liu B,
    6. Han N,
    7. Li J, et al.

    PD-1-expressing B cells suppress CD4(+) and CD8(+) T cells via PD-1/PD-L1-dependent pathway. Mol Immunol. 2019; 109: 20–6.

    OpenUrlCrossRef
34. 34.↵
    2. Olkhanud PB,
    3. Damdinsuren B,
    4. Bodogai M,
    5. Gress RE,
    6. Sen R,
    7. Wejksza K, et al.

    Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res. 2011; 71: 3505–15.

    OpenUrlAbstract/FREE Full Text
35. 35.
    2. Zhang Y,
    3. Morgan R,
    4. Chen C,
    5. Cai Y,
    6. Clark E,
    7. Khan WN, et al.

    Mammary-tumor-educated B cells acquire LAP/TGF-beta and PD-L1 expression and suppress anti-tumor immune responses. Int Immunol. 2016; 28: 423–33.

    OpenUrlCrossRefPubMed
36. 36.
    2. Shen M,
    3. Wang J,
    4. Yu W,
    5. Zhang C,
    6. Liu M,
    7. Wang K, et al.

    A novel MDSC-induced PD-1(-)PD-L1(+) B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties. Oncoimmunology. 2018; 7: e1413520.
37. 37.↵
    2. Guan H,
    3. Lan Y,
    4. Wan Y,
    5. Wang Q,
    6. Wang C,
    7. Xu L, et al.

    PD-L1 mediated the differentiation of tumor-infiltrating CD19(+) B lymphocytes and T cells in invasive breast cancer. Oncoimmunology. 2016; 5: e1075112.
38. 38.↵
    2. Lee-Chang C,
    3. Rashidi A,
    4. Miska J,
    5. Zhang P,
    6. Pituch KC,
    7. Hou D, et al.

    Myeloid-derived suppressive cells promote B cell-mediated immunosuppression via transfer of PD-L1 in glioblastoma. Cancer Immunol Res. 2019; 7: 1928–43.

    OpenUrlAbstract/FREE Full Text
39. 39.↵
    2. Shalapour S,
    3. Font-Burgada J,
    4. Di Caro G,
    5. Zhong Z,
    6. Sanchez-Lopez E,
    7. Dhar D, et al.

    Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015; 521: 94–8.

    OpenUrlCrossRefPubMed
40. 40.↵
    2. Shalapour S,
    3. Lin XJ,
    4. Bastian IN,
    5. Brain J,
    6. Burt AD,
    7. Aksenov AA, et al.

    Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature. 2017; 551: 340–5.

    OpenUrlCrossRef
41. 41.↵
    2. Liu R,
    3. Lu Z,
    4. Gu J,
    5. Liu J,
    6. Huang E,
    7. Liu X, et al.

    MicroRNAs 15A and 16-1 activate signaling pathways that mediate chemotaxis of immune regulatory B cells to colorectal tumors. Gastroenterology. 2018; 154: 637–51.

    OpenUrlCrossRefPubMed
42. 42.↵
    2. Pesce S,
    3. Greppi M,
    4. Grossi F,
    5. Del Zotto G,
    6. Moretta L,
    7. Sivori S, et al.

    PD/1-PD-Ls Checkpoint: insight on the potential role of NK cells. Front Immunol. 2019; 10: 1242.

    OpenUrlPubMed
43. 43.↵
    2. Pesce S,
    3. Greppi M,
    4. Tabellini G,
    5. Rampinelli F,
    6. Parolini S,
    7. Olive D, et al.

    Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol. 2017; 139: 335–46.

    OpenUrlPubMed
44. 44.↵
    2. Benson DM,
    3. Jr. ,
    4. Bakan CE,
    5. Mishra A,
    6. Hofmeister CC,
    7. Efebera Y,
    8. Becknell B, et al.

    The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010; 116: 2286–94.

    OpenUrlAbstract/FREE Full Text
45. 45.
    2. Vari F,
    3. Arpon D,
    4. Keane C,
    5. Hertzberg MS,
    6. Talaulikar D,
    7. Jain S, et al.

    Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood. 2018; 131: 1809–19.

    OpenUrlAbstract/FREE Full Text
46. 46.↵
    2. Hsu J,
    3. Hodgins JJ,
    4. Marathe M,
    5. Nicolai CJ,
    6. Bourgeois-Daigneault MC,
    7. Trevino TN, et al.

    Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018; 128: 4654–68.

    OpenUrlCrossRefPubMed
47. 47.↵
    2. Park SJ,
    3. Namkoong H,
    4. Doh J,
    5. Choi JC,
    6. Yang BG,
    7. Park Y, et al.

    Negative role of inducible PD-1 on survival of activated dendritic cells. J Leukoc Biol. 2014; 95: 621–9.

    OpenUrlCrossRefPubMed
48. 48.↵
    2. Lim TS,
    3. Chew V,
    4. Sieow JL,
    5. Goh S,
    6. Yeong JP,
    7. Soon AL, et al.

    PD-1 expression on dendritic cells suppresses CD8(+) T cell function and antitumor immunity. Oncoimmunology. 2016; 5: e1085146.
49. 49.↵
    2. Karyampudi L,
    3. Lamichhane P,
    4. Krempski J,
    5. Kalli KR,
    6. Behrens MD,
    7. Vargas DM, et al.

    PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-kappaB. Cancer Res. 2016; 76: 239–50.

    OpenUrlAbstract/FREE Full Text
50. 50.↵
    2. Francisco LM,
    3. Sage PT,
    4. Sharpe AH.

    The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236: 219–42.

    OpenUrlCrossRefPubMedWeb of Science
51. 51.↵
    2. Xu L,
    3. Zhang Y,
    4. Tian K,
    5. Chen X,
    6. Zhang R,
    7. Mu X, et al.

    Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects. J Exp Clin Cancer Res. 2018; 37: 261.

    OpenUrl
52. 52.↵
    2. Hamaidia M,
    3. Gazon H,
    4. Hoyos C,
    5. Hoffmann GB,
    6. Louis R,
    7. Duysinx B, et al.

    Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism. JCI Insight. 2019; 4: e128474.
53. 53.↵
    2. Liu J,
    3. Fan L,
    4. Yu H,
    5. Zhang J,
    6. He Y,
    7. Feng D, et al.

    Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and Up-regulate programmed death ligand 1 expression in macrophages. Hepatology. 2019; 70: 241–58.

    OpenUrlPubMed
54. 54.↵
    2. Prima V,
    3. Kaliberova LN,
    4. Kaliberov S,
    5. Curiel DT,
    6. Kusmartsev S.

    COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc Natl Acad Sci U S A. 2017; 114: 1117–22.

    OpenUrlAbstract/FREE Full Text
55. 55.↵
    2. Wen ZF,
    3. Liu H,
    4. Gao R,
    5. Zhou M,
    6. Ma J,
    7. Zhang Y, et al.

    Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1. J Immunother Cancer. 2018; 6: 151.

    OpenUrlAbstract/FREE Full Text
56. 56.↵
    2. Lin C,
    3. He H,
    4. Liu H,
    5. Li R,
    6. Chen Y,
    7. Qi Y, et al.

    Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut. 2019; 68: 1764–73.

    OpenUrlAbstract/FREE Full Text
57. 57.↵
    2. Singhal S,
    3. Stadanlick J,
    4. Annunziata MJ,
    5. Rao AS,
    6. Bhojnagarwala PS,
    7. O’Brien S, et al.

    Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. Sci Transl Med. 2019; 11; eaat1500.
58. 58.↵
    2. Rodrigues CP,
    3. Ferreira AC,
    4. Pinho MP,
    5. de Moraes CJ,
    6. Bergami-Santos PC,
    7. Barbuto JA.

    Tolerogenic IDO(+) dendritic cells are induced by PD-1-expressing mast cells. Front Immunol. 2016; 7: 9.

    OpenUrlPubMed
59. 59.↵
    2. Forsthuber A,
    3. Lipp K,
    4. Andersen L,
    5. Ebersberger S,
    6. Grana C,
    7. Ellmeier W, et al.

    CXCL5 as regulator of neutrophil function in cutaneous melanoma. J Invest Dermatol. 2019; 139: 186–94.

    OpenUrl
60. 60.↵
    2. Noman MZ,
    3. Desantis G,
    4. Janji B,
    5. Hasmim M,
    6. Karray S,
    7. Dessen P, et al.

    PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014; 211: 781–90.

    OpenUrlAbstract/FREE Full Text
61. 61.↵
    2. Fleming V,
    3. Hu X,
    4. Weller C,
    5. Weber R,
    6. Groth C,
    7. Riester Z, et al.

    Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. Cancer Res. 2019; 79: 4715–28.

    OpenUrlAbstract/FREE Full Text
62. 62.↵
    2. Song S,
    3. Yuan P,
    4. Wu H,
    5. Chen J,
    6. Fu J,
    7. Li P, et al.

    Dendritic cells with an increased PD-L1 by TGF-beta induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells. Int Immunopharmacol. 2014; 20: 117–23.

    OpenUrlCrossRefPubMed
63. 63.↵
    2. Bloch O,
    3. Crane CA,
    4. Kaur R,
    5. Safaee M,
    6. Rutkowski MJ,
    7. Parsa AT.

    Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013; 19: 3165–75.

    OpenUrlAbstract/FREE Full Text
64. 64.↵
    2. Roux C,
    3. Jafari SM,
    4. Shinde R,
    5. Duncan G,
    6. Cescon DW,
    7. Silvester J, et al.

    Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proc Natl Acad Sci U S A. 2019; 116: 4326–35.

    OpenUrlAbstract/FREE Full Text
65. 65.↵
    2. Jing W,
    3. Guo X,
    4. Wang G,
    5. Bi Y,
    6. Han L,
    7. Zhu Q, et al.

    Breast cancer cells promote CD169(+) macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages. Int Immunopharmacol. 2019; 78: 106012.

    OpenUrl
66. 66.↵
    2. Zhang Y,
    3. Lee C,
    4. Geng S,
    5. Li L.

    Enhanced tumor immune surveillance through neutrophil reprogramming due to Tollip deficiency. JCI Insight. 2019; 4: e122939.
67. 67.↵
    2. Zhang Y,
    3. Diao N,
    4. Lee CK,
    5. Chu HW,
    6. Bai L,
    7. Li L.

    Neutrophils deficient in innate suppressor IRAK-M enhances anti-tumor immune responses. Mol Ther. 2019; 28: 89–99.

    OpenUrl
68. 68.↵
    2. Terawaki S,
    3. Chikuma S,
    4. Shibayama S,
    5. Hayashi T,
    6. Yoshida T,
    7. Okazaki T, et al.

    IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol. 2011; 186: 2772–9.

    OpenUrlAbstract/FREE Full Text
69. 69.↵
    2. Sun L,
    3. Wang Q,
    4. Chen B,
    5. Zhao Y,
    6. Shen B,
    7. Wang X, et al.

    Human gastric cancer mesenchymal stem cell-derived IL15 contributes to tumor cell epithelial-mesenchymal transition via upregulation tregs ratio and PD-1 expression in CD4(+)T cell. Stem Cells Dev. 2018; 27: 1203–14.

    OpenUrl
70. 70.↵
    2. Lu P,
    3. Youngblood BA,
    4. Austin JW,
    5. Mohammed AU,
    6. Butler R,
    7. Ahmed R, et al.

    Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection. J Exp Med. 2014; 211: 515–27.

    OpenUrlAbstract/FREE Full Text
71. 71.↵
    2. Mathieu M,
    3. Cotta-Grand N,
    4. Daudelin JF,
    5. Thebault P,
    6. Labrecque N.

    Notch signaling regulates PD-1 expression during CD8(+) T-cell activation. Immunol Cell Biol. 2013; 91: 82–8.

    OpenUrlCrossRefPubMed
72. 72.↵
    2. Chang CH,
    3. Curtis JD,
    4. Maggi LB Jr.,
    5. Faubert B,
    6. Villarino AV,
    7. O’Sullivan D, et al.

    Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013; 153: 1239–51.

    OpenUrlCrossRefPubMedWeb of Science
73. 73.↵
    2. Youngblood B,
    3. Oestreich KJ,
    4. Ha SJ,
    5. Duraiswamy J,
    6. Akondy RS,
    7. West EE, et al.

    Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity. 2011; 35: 400–12.

    OpenUrlCrossRefPubMedWeb of Science
74. 74.↵
    2. Okada M,
    3. Chikuma S,
    4. Kondo T,
    5. Hibino S,
    6. Machiyama H,
    7. Yokosuka T, et al.

    Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells. Cell Rep. 2017; 20: 1017–28.

    OpenUrlCrossRefPubMed
75. 75.↵
    2. Mao Y,
    3. Wang Y,
    4. Dong L,
    5. Zhang Q,
    6. Wang C,
    7. Zhang Y, et al.

    Circulating exosomes from esophageal squamous cell carcinoma mediate the generation of B10 and PD-1(high) Breg cells. Cancer Sci. 2019; 110: 2700–10.

    OpenUrl
76. 76.↵
    2. Flies DB,
    3. Chen L.

    The new B7s: playing a pivotal role in tumor immunity. J Immunother. 2007; 30: 251–60.

    OpenUrlCrossRefWeb of Science
77. 77.↵
    2. Freeman GJ,
    3. Long AJ,
    4. Iwai Y,
    5. Bourque K,
    6. Chernova T,
    7. Nishimura H, et al.

    Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192: 1027–34.

    OpenUrlAbstract/FREE Full Text
78. 78.↵
    2. Keir ME,
    3. Butte MJ,
    4. Freeman GJ,
    5. Sharpe AH.

    PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26: 677–704.

    OpenUrlCrossRefPubMedWeb of Science
79. 79.↵
    2. Versteven M,
    3. Van den Bergh JMJ,
    4. Marcq E,
    5. Smits ELJ,
    6. Van Tendeloo VFI,
    7. Hobo W, et al.

    Dendritic cells and programmed death-1 blockade: a joint venture to combat cancer. Front Immunol. 2018; 9: 394.

    OpenUrl
80. 80.↵
    2. Tel J,
    3. Hato SV,
    4. Torensma R,
    5. Buschow SI,
    6. Figdor CG,
    7. Lesterhuis WJ, et al.

    The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. Cancer Immunol Immunother. 2012; 61: 1101–11.

    OpenUrlCrossRefPubMed
81. 81.↵
    2. Hartley G,
    3. Regan D,
    4. Guth A,
    5. Dow S.

    Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-alpha. Cancer Immunol Immunother. 2017; 66: 523–35.

    OpenUrl
82. 82.↵
    2. Bally AP,
    3. Lu P,
    4. Tang Y,
    5. Austin JW,
    6. Scharer CD,
    7. Ahmed R, et al.

    NF-kappaB regulates PD-1 expression in macrophages. J Immunol. 2015; 194: 4545–54.

    OpenUrlAbstract/FREE Full Text
83. 83.↵
    2. Lu C,
    3. Redd PS,
    4. Lee JR,
    5. Savage N,
    6. Liu K.

    The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. Oncoimmunology. 2016; 5: e1247135.
84. 84.↵
    2. Ren D,
    3. Hua Y,
    4. Yu B,
    5. Ye X,
    6. He Z,
    7. Li C, et al.

    Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020; 19: 19.

    OpenUrlPubMed
85. 85.↵
    2. Seliger B.

    Basis of PD1/PD-L1 therapies. J Clin Med. 2019; 8: 2168.

    OpenUrl
86. 86.↵
    2. Wu Y,
    3. Chen W,
    4. Xu ZP,
    5. Gu W.

    PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol. 2019; 10: 2022.

    OpenUrlPubMed